Clinical Trial Update: Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial investigates the optimal duration of dual antiplatelet therapy after distal revascularization in chronic limb-threatening ischemia, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-threatening Ischemia

Snippet

Sponsor: Fondation Hôpital Saint-Joseph | Conditions: CLTI Defined as Rutherford Category 4 or 5 | Phase 3 | Status: NOT_YET_RECRUITING